Gilead's Truvada Is Approved by the FDA
August 30, 2004
The Food and Drug Administration approved Gilead's Truvada, a one-tablet, once-a-day dosed co-formulation of Viread and Emtriva. This medication combines 200 mg of emtricitabine and 300 mg of tenofovir fumarate.
This once-a-day new combination may make it easier for doctors when prescribing new regimens. Truvada must be taken in combination with other anti-HIV medications to achieve maximum viral suppression.
The company is planning to sell Truvada to the developing world at a not-profit price through Gilead's Access Program. The developing world counts for more than 70% of all infections. For more information on Truvada, go to Gilead.com, talk to your doctor or call the STEP Program at 1-888-399-7837.
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.